OLADAPO LAPITE: Open Payments
NPI 1003837287 · MONROE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$946 in 42 payments from 12 companies in 2025. Trend: 2023 $586 · 2024 $873 · 2025 $946
Food & beverage: $946
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $179 |
| Novo Nordisk Inc | 7 | $145 |
| ABBVIE INC. | 5 | $115 |
| Lilly USA, LLC | 5 | $112 |
| Sumitomo Pharma America, Inc. | 4 | $95 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $87 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $76 |
| GlaxoSmithKline, LLC. | 2 | $47 |
| Verona Pharma, Inc. | 1 | $28 |
| Exact Sciences Corporation | 1 | $27 |
Products named: VRAYLAR, JARDIANCE, AIRSUPRA, GEMTESA, MOUNJARO, Rybelsus, CAPLYTA, Ozempic.
Industry payments across LA — which companies pay providers there.
